Fourth Quarter 2022 and Subsequent Highlights: Announced topline results from Phase 1 study of RT-102. In December 2022, Rani announced topline results from Part 2 (repeat-dose portion) of the ...

Rani Therapeutics Holdings ... platform and highlight the important advancements that Rani has achieved in its pipeline over the past year. Then I will share how we are leveraging the RaniPill ...

Rani Therapeutics Holdings ... and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti ...

Rani Therapeutics Holdings ... a lack of independent advancements or breakthroughs in their own product pipeline. The inclusion of forward-looking statements highlights potential risks and ...

Rani Therapeutics (NASDAQ ... in the field of oral drug delivery and need for lots of cash to support the pipeline. There are 2 methods to allow oral delivery of injectables; (1) chemical methods ...

Despite the revised timeline, Canaccord Genuity maintained a Buy rating on the company's shares, indicating its continued confidence in the potential of Rani Therapeutics' pipeline. These are the ...

The firm's pipeline includes RT-114, a RaniPill capsule containing a dual-agonist for GLP-1 and GLP-2, named PG-102. Rani Therapeutics is preparing to initiate a Phase 1 trial for RT-114. Moreover, ...

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund ...